News & Insights

Stay informed with transaction announcements, firm news, and strategic insights from D. Boral Capital.

News & Insights

Published by D. Boral Capital

D. Boral Capital Acted as Sole Bookrunner to SPACSphere Acquisition Corp. (Nasdaq: SSACU) in Connection with its $172,500,000 Initial Public Offering

D. Boral Capital Acted as Sole Bookrunner to SPACSphere Acquisition Corp. (Nasdaq: SSACU) in Connection with its $172,500,000 Initial Public Offering

Read More →
D. Boral Capital Acted as Sole Bookrunner to White Pearl Acquisition Corp. (NYSE: WPACU) in Connection with its $115,000,000 Initial Public Offering

D. Boral Capital Acted as Sole Bookrunner to White Pearl Acquisition Corp. (NYSE: WPACU) in Connection with its $115,000,000 Initial Public Offering

Read More →
D. Boral Capital Acted as Sole Bookrunner to K2 Capital Acquisition Corporation (Nasdaq: KTWOU) in Connection with its $138,000,000 Initial Public Offering

D. Boral Capital Acted as Sole Bookrunner to K2 Capital Acquisition Corporation (Nasdaq: KTWOU) in Connection with its $138,000,000 Initial Public Offering

Read More →
D. Boral Capital Acted as Sole Bookrunner to Xsolla SPAC 1 (Nasdaq: XSLL) in Connection with its ~$204,000,000 Initial Public Offering

D. Boral Capital Acted as Sole Bookrunner to Xsolla SPAC 1 (Nasdaq: XSLL) in Connection with its ~$204,000,000 Initial Public Offering

Read More →
D. Boral Capital Acted as Sole Bookrunner to GigCapital9 Corp. (Nasdaq: GIX) in Connection with its $253,000,000 Initial Public Offering

D. Boral Capital Acted as Sole Bookrunner to GigCapital9 Corp. (Nasdaq: GIX) in Connection with its $253,000,000 Initial Public Offering

Read More →
D. Boral Capital Acted as Exclusive Placement Agent to Mobix Labs, Inc. (Nasdaq: MOBX) in Connection with its $6,000,000 Follow-On Offering

D. Boral Capital Acted as Exclusive Placement Agent to Mobix Labs, Inc. (Nasdaq: MOBX) in Connection with its $6,000,000 Follow-On Offering

Read More →
Reframing Alzheimer’s Drug Development: Clinical Signals, Regulatory Review, and the Path Forward for ANAVEX®2-73

Reframing Alzheimer’s Drug Development: Clinical Signals, Regulatory Review, and the Path Forward for ANAVEX®2-73

Read More →
D. Boral Capital Acted as Lead Underwriter to Aduro Clean Technologies Inc. (Nasdaq: ADUR) in Connection with its $20,000,000 Underwritten Public Offering

D. Boral Capital Acted as Lead Underwriter to Aduro Clean Technologies Inc. (Nasdaq: ADUR) in Connection with its $20,000,000 Underwritten Public Offering

Read More →
D. Boral Capital Acted as Financial Advisor to GlobalTech Corporation (OTCID: GTLK) in Connection with its ~$11,000,000 Acquisition of Controlling Stake in Moda In Pelle

D. Boral Capital Acted as Financial Advisor to GlobalTech Corporation (OTCID: GTLK) in Connection with its ~$11,000,000 Acquisition of Controlling Stake in Moda In Pelle

Read More →
Advancing Inflammatory Disease Treatment: Insights & Breakthroughs from Enlivex’s Knee Osteoarthritis Program

Advancing Inflammatory Disease Treatment: Insights & Breakthroughs from Enlivex’s Knee Osteoarthritis Program

Read More →
D. Boral Capital Acted as Placement Agent to Robo.ai Inc. (Nasdaq: AIIO) in Connection with the First Tranche of Its $180,000,000 PIPE

D. Boral Capital Acted as Placement Agent to Robo.ai Inc. (Nasdaq: AIIO) in Connection with the First Tranche of Its $180,000,000 PIPE

Read More →
D. Boral Capital Acted as Co-Lead Bookrunner to New America Acquisition I Corp. (NYSE: NWAXU) in Connection with its $345,000,000 Initial Public Offering

D. Boral Capital Acted as Co-Lead Bookrunner to New America Acquisition I Corp. (NYSE: NWAXU) in Connection with its $345,000,000 Initial Public Offering

Read More →